Home / Market News / $OBIO

$OBIO news and market catalysts

The 9 most recent market catalysts affecting $OBIO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

9 catalysts 1 high impact 5 bullish 1 bearish Biotechnology
Nov 10, 2026 Corporate Catalyst Bullish Impact 75
Orchestra BioMed Reports Third Quarter 2026 Financial Results and Business Updates
Orchestra BioMed announced the completion of enrollment for its BACKBEAT Global Pivotal Trial and accelerating enrollment for its Virtue Trial, indicating strong operational execut…
Nov 6, 2026 Corporate Catalyst Neutral Impact 75
Orchestra BioMed Prices $75 Million Public Offering of Common Stock
Orchestra BioMed Holdings, Inc. priced a public offering of 15 million shares at $5.00 per share, aiming to raise $75 million. This capital infusion is crucial for funding the comp…
Nov 5, 2026 Corporate Catalyst Neutral Impact 75
Orchestra BioMed Announces Proposed Public Offering of Common Stock
Orchestra BioMed's announcement of a public offering of common stock is a significant event for the company. While the stated purpose of funding research and general corporate need…
Oct 22, 2026 Corporate Catalyst Neutral Impact 65
Orchestra BioMed to Host R&D Day
Orchestra BioMed is holding an R&D Day to discuss its AVIM Therapy and Virtue SAB, both of which are in pivotal clinical trials. This event is significant because it provides a pla…
Sep 15, 2026 Corporate Catalyst Bullish Impact 65
Orchestra BioMed Announces Receipt Of $6.1M Milestone Payment From Haemonetics' Acquisition Of Vivasure Medica
This headline represents a positive corporate catalyst for Orchestra BioMed (OBIO) as it receives a significant non-dilutive cash injection, strengthening its balance sheet and pot…
Sep 10, 2026 Corporate Catalyst Bullish Impact 75
Orchestra BioMed shares are trading higher after BTIG upgraded the stock from Neutral to Buy rating and announced a $10 price target.
This headline represents a significant corporate catalyst for Orchestra BioMed. An analyst upgrade from 'Neutral' to 'Buy' by a reputable firm like BTIG, coupled with a substantial…
Sep 10, 2026 Corporate Catalyst Bullish Impact 55
BTIG Upgrades Orchestra BioMed Hldgs to Buy, Announces $10 Price Target
BTIG analyst Marie Thibault upgraded Orchestra BioMed Holdings (OBIO) from Neutral to Buy and announced a $10 price target. This upgrade reflects a more optimistic outlook from a r…
Aug 11, 2026 Corporate Catalyst Bullish Impact 60
Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10
Piper Sandler analyst Matt O'Brien has reaffirmed an 'Overweight' rating for Orchestra BioMed Holdings (OBIO) and raised the price target from $9 to $10. This move indicates that t…
Aug 10, 2026 Corporate Catalyst Bearish Impact 95
Orchestra BioMed Hldgs Q2 EPS $(0.38) Misses $(0.37) Estimate, Sales $88.000K Miss $121.400K Estimate
Orchestra BioMed Holdings (OBIO) reported Q2 earnings per share of $(0.38), missing the analyst consensus of $(0.37), and sales of $88,000, significantly missing the $121,400 estim…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.